CIPLA
500087Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed press release titled "Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)"
Cipla Ltd is a leading global pharmaceutical company headquartered in Mumbai, India. Established in 1935, Cipla is recognized for its broad portfolio of generic and branded medicines spanning key therapeutic areas including respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system. Operating in over 80 countries, Cipla provides affordable medications through over 1,500 products across multiple formulations and dosage forms, catering to both developed and emerging markets.
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed press release titled "Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)"
Update On USFDA Inspection At Invagen Manufacturing Facility In Central Islip, Long Island, NY, USA
Please find enclosed disclosure.
Announcement under Regulation 30 (LODR)-Restructuring
Please find enclosed disclosure.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein mention the schedule of Analyst / Institutional Investor Meeting with the Company.
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
In terms of regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Admisnistrative Committee of the Company on 26th August, 2026 has allotted 5,281 fully paid up equity shares of INR 2 each pursuant to exercise of employee stock options/ stock appreciation rights under the Employee Stock Option Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021 of the Company.
USFDA Inspection At Company'S Manufacturing Facility In Pithampur, India
Please find enclosed disclosure
Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Cipla has informed the exchange about receipt of order from Hon''ble NCLT, Mumbai Bench
Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find attached disclosure on ESG Ratings.
Update On USFDA Inspection At Invagen Manufacturing Facility In Hauppauge, Long Island, New York, USA
Please find enclosed intimation.
Cipla Ltd
About
Cipla Ltd is a leading global pharmaceutical company headquartered in Mumbai, India. Established in 1935, Cipla is recognized for its broad portfolio of generic and branded medicines spanning key therapeutic areas including respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system. Operating in over 80 countries, Cipla provides affordable medications through over 1,500 products across multiple formulations and dosage forms, catering to both developed and emerging markets.
Cipla’s integrated business model encompasses research and development, manufacturing, and global distribution. The company continues to focus on innovation in drug delivery, leveraging manufacturing excellence, and digital transformation to drive access to high-quality healthcare worldwide. Its robust presence in India is complemented by strong operations in North America, South Africa, and several key international markets.
Business Model & Strategy
Cipla earns revenues primarily from the development, manufacturing, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). Its business is diversified across geographies, with a strong presence in the Indian generics market and significant operations in North America, Africa, and select regulated and emerging markets. The company employs a B2B and B2C strategy, selling products under its own brands as well as supplying to major global pharmaceutical companies.
Cipla’s growth strategies emphasize product innovation, specialty and complex generics, expansion in key therapeutic segments (notably respiratory and chronic care), as well as inorganic expansion through targeted acquisitions and strategic partnerships. The company invests heavily in R&D and leverages digital initiatives for process optimization and patient-centric solutions.
Management Overview
13 MembersMr.Y K Hamied
Non-Executive - Non Independent Director-Chairperson related to PromoterMr.Umang Vohra
Executive Director-CEO-MDMr.Adil Zainulbhai
Non-Executive - Non Independent DirectorMr.Robert Stewart
Non-Executive - Independent DirectorMr.Prathivadibhayankara Rajagopalan Ramesh
Non-Executive - Independent DirectorMr.Mandar Purushottam Vaidya
Non-Executive - Independent DirectorMr.Balram Bhargava
Non-Executive - Independent DirectorMs.Sharmila Paranjpe
Non-Executive - Independent DirectorMr.Abhijit Jagdish Joshi
Non-Executive - Non Independent DirectorMr.Kamil Hamied
Non-Executive - Non Independent DirectorMs.Maya Hari
Non-Executive - Independent DirectorMr.AshishAdukia
Chief Financial OfficerMr.RajendraChopra
Company Secretary & Compliance OfficerAwards & Recognition
6 Awards- Featured in Forbes Global 2000 (2024)
- Ranked among India's Most Trusted Brands in healthcare (2024, Brand Trust Report)
- ‘Best Governed Company’ – ICSI National Awards for Excellence in Corporate Governance (2023)
- MSCI ESG rating: ‘A’ (2024)
- Included in Dow Jones Sustainability Emerging Markets Index (2023)
- CII National Award for Sustainable Environment Practices (2023)
Market Information
Company Timeline
89+ Years of Excellence | 10 Major Milestones
Cipla founded by Dr. K.A. Hamied in Mumbai, India
Commenced manufacturing of active pharmaceutical ingredients (APIs)
Pioneered affordable anti-cancer drugs in India
Listed on Bombay Stock Exchange (BSE)
Listed on National Stock Exchange (NSE)
Global impact with low-cost antiretroviral AIDS therapies
Acquired Invagen Pharmaceuticals (USA), entering US generics market
Launched COVID-19 treatments (Remdesivir/Cipremi, Favipiravir)
Expanded digital health initiatives, entered novel delivery systems
Strengthened US and specialty pipeline; ESG and sustainability recognitions
The Next Evolution
Contact Information
Registered Office
Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel
Tel: 022-24826000, 24826951,
Fax: 022-24826120,24826893,
Email: cosecretary@cipla.com; contactus@cipla.com
Website: cipla.com
Corporate Actions
14| Purpose | Ex Date | Record Date | BC Start | BC End |
|---|---|---|---|---|
Final Dividend ₹13 per share | 05 Jun 2026 Friday | 05 Jun 2026 Friday | - | - |
Final Dividend ₹13 per share | 27 Jun 2025 Friday | 27 Jun 2025 Friday | - | - |
Special Dividend ₹3 per share | 27 Jun 2025 Friday | 27 Jun 2025 Friday | - | - |
Final Dividend ₹13 per share | 02 Aug 2024 Friday | 02 Aug 2024 Friday | - | - |
Final Dividend ₹8.50 per share | 21 Jul 2023 Friday | 21 Jul 2023 Friday | - | - |
Dividend ₹5 per share | 08 Aug 2022 Monday | 10 Aug 2022 Wednesday | - | - |
Dividend ₹5 per share | 09 Aug 2021 Monday | - | 11 Aug 2021 Wednesday | 25 Aug 2021 Wednesday |
Interim Dividend ₹3 per share | 19 Mar 2020 Thursday | 20 Mar 2020 Friday | - | - |
Special Dividend ₹1 per share | 19 Mar 2020 Thursday | 20 Mar 2020 Friday | - | - |
Dividend ₹3 per share | 31 Jul 2019 Wednesday | - | 02 Aug 2019 Friday | 16 Aug 2019 Friday |
Dividend ₹3 per share | 13 Aug 2018 Monday | - | 16 Aug 2018 Thursday | 30 Aug 2018 Thursday |
Dividend ₹2 per share | 26 Jul 2017 Wednesday | - | 28 Jul 2017 Friday | 11 Aug 2017 Friday |
Dividend ₹2 per share | 12 Sep 2016 Monday | - | 15 Sep 2016 Thursday | 28 Sep 2016 Wednesday |
Dividend ₹2 per share | 11 Aug 2015 Tuesday | - | 13 Aug 2015 Thursday | 27 Aug 2015 Thursday |
₹1,13,817 Cr.
₹1,412
₹1,673 / 1,166
33.76
₹427.35
3.3
₹41.74
₹2.00
0.92 %
Manage Ratio
FINANCIALS
| Annual Results | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | - | - | - | 16,839 | 17,476 | 19,426 | 22,044 | 23,229 | 26,521 | 28,409 | 29,045 | 29,159 |
| Expenses | - | - | - | 14,760 | 15,298 | 16,136 | 18,369 | 19,008 | 20,624 | 21,589 | 23,545 | 24,347 |
| Profit | - | - | - | 1,492 | 1,500 | 2,389 | 2,547 | 2,833 | 4,154 | 5,269 | 3,862 | 3,356 |
| Tax | - | - | - | 570 | 631 | 889 | 934 | 1,203 | 1,547 | 1,530 | 1,354 | 1,171 |
| EPS | - | - | - | 19 | 19 | 30 | 31 | 35 | 51 | 65 | 48 | 9.77 |
| Ratios | - |
Cash Flow
Consolidated Figures in Rs. Crores
| Annual Balance Sheet | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | - | - | - | 23,963 | 23,663 | 25,152 | 27,101 | 29,463 | 32,718 | 37,387 | 42,496 | - |
| Equity And Liabilities | - | - | - | 23,963 | 23,663 | 25,152 | 27,101 | 29,463 | 32,718 | 37,387 | 42,496 | - |
Shareholding Pattern
Numbers in Percentages
| Quarterly SHP Announcement Date | Mar 2016 12 Apr '16 | Mar 2017 31 Mar '17 | Mar 2018 31 Mar '18 | Mar 2019 16 Apr '19 | Mar 2020 14 May '20 | Mar 2021 21 Apr '21 | Mar 2022 21 Apr '22 | Mar 2023 17 Apr '23 | Mar 2024 19 Apr '24 | Mar 2025 21 Apr '25 | Mar 2026 11 Aug '26 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goverments | - | - | - | - | - | - | - | - | - | - | - | - |
| Promoter And Promoter Group | - | - | - | 36.70% | 36.68% | 36.73% | 33.63% | 33.55% | 33.47% | 29.20% | 29.21% | - |
| Non Institutions | - | - | - | 22.49% | 22.71% | 22.84% | 17.73% | 16.94% | 16.28% | 16.37% | 16.25% | - |
| FII | - | - | - | - | - | - | - | 27.42% | 25.83% | 26.28% | 22.56% | - |
| DII | - | - | - | - | - | - | - | 22.10% | 24.42% | 28.15% | 31.97% | - |
| Total | - | - | - | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - |
Cipla Ltd
Cipla Ltd
Cipla Ltd is a leading global pharmaceutical company headquartered in Mumbai, India. Established in 1935, Cipla is recognized for its broad portfolio of generic and branded medicines spanning key therapeutic areas including respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system. Operating in over 80 countries, Cipla provides affordable medications through over 1,500 products across multiple formulations and dosage forms, catering to both developed and emerging markets.
Cipla’s integrated business model encompasses research and development, manufacturing, and global distribution. The company continues to focus on innovation in drug delivery, leveraging manufacturing excellence, and digital transformation to drive access to high-quality healthcare worldwide. Its robust presence in India is complemented by strong operations in North America, South Africa, and several key international markets.
Cipla earns revenues primarily from the development, manufacturing, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). Its business is diversified across geographies, with a strong presence in the Indian generics market and significant operations in North America, Africa, and select regulated and emerging markets. The company employs a B2B and B2C strategy, selling products under its own brands as well as supplying to major global pharmaceutical companies.
Cipla’s growth strategies emphasize product innovation, specialty and complex generics, expansion in key therapeutic segments (notably respiratory and chronic care), as well as inorganic expansion through targeted acquisitions and strategic partnerships. The company invests heavily in R&D and leverages digital initiatives for process optimization and patient-centric solutions.
Featured in Forbes Global 2000 (2024)
Ranked among India's Most Trusted Brands in healthcare (2024, Brand Trust Report)
‘Best Governed Company’ – ICSI National Awards for Excellence in Corporate Governance (2023)
MSCI ESG rating: ‘A’ (2024)
Included in Dow Jones Sustainability Emerging Markets Index (2023)
CII National Award for Sustainable Environment Practices (2023)
Cipla founded by Dr. K.A. Hamied in Mumbai, India
Commenced manufacturing of active pharmaceutical ingredients (APIs)
Pioneered affordable anti-cancer drugs in India
Listed on Bombay Stock Exchange (BSE)
Listed on National Stock Exchange (NSE)
Global impact with low-cost antiretroviral AIDS therapies
Acquired Invagen Pharmaceuticals (USA), entering US generics market
Launched COVID-19 treatments (Remdesivir/Cipremi, Favipiravir)
Expanded digital health initiatives, entered novel delivery systems
Strengthened US and specialty pipeline; ESG and sustainability recognitions
Peer Comparison
| S.No. | Company Name | CMP (₹) | Market Cap (₹ Cr) | Div Yld (%) | NP Qtr (₹ Cr) | Qtr Profit Var (%) | Sales Qtr (₹ Cr) | Qtr Sales Var (%) | ROCE (%) | ROE (%) | Book Value (₹) | EPS TTM (₹) | TTMPE Ratio (₹) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon
Heatmap View
Premium Feature| Company | CMP (₹) | MCap (₹ Cr) | EPS TTM (₹) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Financial Ratios
Premium Feature| Company Name | P/E (TTM) | EPS (₹) | D/E | NPM | GPM | ROE (%) | ROCE (%) | P/B | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon